Skip to search formSkip to main contentSkip to account menu

IDH1 and IDH2 mutations in gliomas.

TLDR
Mutations of NADP(+)-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur in a majority of several types of malignant gliomas.
View on PubMed (opens in a new tab)

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

TLDR
The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies.
View on PubMed (opens in a new tab)

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

TLDR
Bvacizumab and irinotecan is an effective treatment for recurrent glioblastoma multiforme and has moderate toxicity.
View on PubMed (opens in a new tab)

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

TLDR
The combination of bevacizumab and irinotecan is an active regimen for recurrent grade III-IV glioma with acceptable toxicity and no central nervous system hemorrhages occurred.
View on Publisher (opens in a new tab)

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

TLDR
It is suggested that the neoadjuvant administration of PD-1 blockade enhances both the local and systemic antitumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor.
View on Springer (opens in a new tab)

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

TLDR
EGFRvIII-targeted vaccination in patients with GBM warrants investigation in a phase III, randomized trial.
View on PubMed (opens in a new tab)

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

TLDR
It is demonstrated that a strategy that uses multi-epitope, personalized neoantigen vaccination, which has previously been tested in patients with high-risk melanoma, is feasible for tumours such as glioblastoma, which typically have a relatively low mutation load and an immunologically ‘cold’ tumour microenvironment.
View on Springer (opens in a new tab)

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

TLDR
Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases.
View on Wolters Kluwer (opens in a new tab)

Phase II trial of gefitinib in recurrent glioblastoma.

TLDR
Gefitinib is well tolerated and has activity in patients with recurrent glioblastoma and further study of this agent at higher doses is warranted.
View on PubMed (opens in a new tab)

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

View on PubMed (opens in a new tab)
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)